VeriOsteo OP
VeriOsteo OP is the first AI-assisted bone mineral density (BMD) screening software approved by Taiwan FDA. Developed in collaboration with Taichung Veterans General Hospital, the software analyzes standard chest X-ray images to predict BMD values, calculate T-scores, and identify patients with suspected osteoporosis—all within 30 seconds.
Product Overview
Osteoporosis ranks as the second most prevalent disease globally after cardiovascular conditions, with Taiwan recording the highest hip fracture incidence in the Asia-Pacific region. Traditional bone density assessment requires specialized DXA (dual-energy X-ray absorptiometry) equipment, limiting screening accessibility. VeriOsteo OP transforms routine chest X-rays into osteoporosis screening tools, enabling early detection during standard health examinations without additional imaging procedures.
The software addresses a critical healthcare gap: osteoporosis typically presents without symptoms until fracture occurrence, at which point mortality rates reach approximately 20% with most patients unable to regain independent self-care. By leveraging existing chest X-ray infrastructure, VeriOsteo OP enables opportunistic screening for BMD abnormalities during routine medical encounters.
Key Features
Approved in Taiwan in 2023 and subsequently in Thailand, Malaysia, Singapore, and Indonesia, VeriOsteo OP screens chest X-rays for bone mineral density abnormalities in 30 seconds.
- Chest X-Ray Analysis: Extracts BMD information from standard chest radiographs without specialized equipment
- T-Score Calculation: Automatically computes T-scores from predicted BMD values for clinical interpretation
- Rapid Processing: Delivers screening results within 30 seconds
- Batch Mode: Analyzes multiple images simultaneously with CSV output for institutional screening programs
- Personalized Reports: Generates individual patient reports including X-ray images, AI analysis, BMD values, and T-scores
Technical Specifications
VeriOsteo OP is an AI bone mineral density screening tool by Acer Medical, analyzing standard chest X-rays to predict T-scores with approximately 90% accuracy in 30 seconds.
| Parameter | Specification |
|---|---|
| Screening Accuracy | ~90% |
| Analysis Time | 30 seconds |
| Input | Standard chest X-ray images |
| Output | BMD prediction, T-score, risk recommendation |
| Analysis Region | Spinal regions from chest X-ray |
| Batch Processing | Yes, CSV output supported |
Clinical Applications
VeriOsteo OP targets hospitals, health examination centers, and primary care clinics conducting routine chest X-rays. The software analyzes spinal regions visible in standard posteroanterior chest radiographs to estimate lumbar bone density values. Clinical implementation at Taichung Veterans General Hospital demonstrated effective identification of bone density abnormalities, enabling appropriate patient education and referral for specialized osteoporosis consultation.
The product reduces dependency on dedicated DXA facilities, particularly benefiting healthcare settings in areas with limited access to bone densitometry services. Healthcare professionals receive AI-generated risk assessments that inform decisions regarding further diagnostic workup or preventive intervention.
Regulatory Status
| Region | Status | Date |
|---|---|---|
| Taiwan (TFDA) | Approved | 2023 |
| Thailand (Thai FDA) | Approved | 2024 |
| Indonesia (MoH) | Approved | 2024 |
| Singapore (HSA) | Approved | 2024 |
| Malaysia (MDA) | Approved | 2024 |
| China (NMPA) | Not Applied | - |
| Europe (CE) | Not Applied | - |
| USA (FDA) | Not Applied | - |
Recognition
VeriOsteo OP received the 2024 Taiwan Excellence Golden Award and the 21st National Innovation Award, recognizing its contribution to accessible osteoporosis screening technology.
Frequently Asked Questions
How does VeriOsteo OP detect bone density from chest X-rays?
VeriOsteo OP uses deep learning algorithms trained on clinical data to analyze spinal regions visible in chest X-ray images. The AI predicts bone mineral density values and calculates corresponding T-scores, which indicate bone density relative to healthy young adult reference values.
Is VeriOsteo OP a replacement for DXA scanning?
VeriOsteo OP functions as a screening tool that identifies patients with suspected BMD abnormalities who may benefit from confirmatory DXA examination. It enables opportunistic screening during routine chest X-rays rather than replacing definitive bone densitometry diagnosis.
What clinical evidence supports VeriOsteo OP accuracy?
Clinical validation was published in Diagnostics journal (2024) titled “Clinical Validation of a Deep Learning-Based Software for Lumbar Bone Mineral Density and T-Score Prediction from Chest X-ray Images,” demonstrating approximately 90% screening accuracy.
Sources
Publicly available references used for the data on this page. See data methodology for verification standards.